Kymera Therapeutics financials
$110.51−1.33%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.0M | $34.4M | $2.9M | $2.8M | $11.5M | $22.1M | $7.4M | $3.7M | $25.6M | $10.3M | $47.9M | $4.7M |
| Gross profit | $65.0M | $34.4M | $2.9M | $2.8M | $11.5M | $22.1M | $7.4M | $3.7M | $25.6M | $10.3M | $47.9M | $4.7M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$75.6M | -$84.2M | -$97.9M | -$92.5M | -$84.6M | -$74.5M | -$80.8M | -$72.1M | -$50.9M | -$57.8M | -$19.3M | -$57.5M |
| Net income | -$61.2M | -$69.2M | -$87.0M | -$82.2M | -$76.6M | -$65.6M | -$70.8M | -$62.5M | -$42.1M | -$48.6M | -$14.4M | -$52.9M |
| Net margin | −94.2% | −201.5% | −3030.7% | −2973.0% | −667.6% | −296.7% | −956.9% | −1670.3% | −164.0% | −472.0% | −30.0% | −1118.2% |
| Diluted EPS | $-0.62 | $-0.71 | $-0.97 | $-0.94 | $-0.95 | $-0.82 | $-0.88 | $-0.82 | $-0.58 | $-0.69 | $-0.25 | $-0.90 |
| EBITDA | -$73.6M | -$82.2M | -$95.9M | -$86.5M | -$82.5M | -$72.5M | -$78.8M | -$70.1M | -$49.0M | -$51.4M | -$19.3M | -$56.6M |
| Operating cash flow | -$54.1M | -$88.8M | -$66.7M | -$27.1M | -$59.9M | -$79.2M | -$61.8M | -$50.2M | -$42.9M | -$39.6M | $8.0M | -$31.6M |
| Free cash flow | -$54.5M | -$89.3M | -$66.9M | -$27.3M | -$60.6M | -$79.6M | -$62.7M | -$50.4M | -$47.6M | -$47.0M | -$3.6M | -$39.7M |
| Diluted shares | 98.2M | 97.5M | 90.1M | 87.3M | 80.4M | 80.1M | 80.2M | 76.1M | 73.1M | 70.8M | 58.5M | 58.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $124.5M | $144.1M | $357.0M | $112.9M | $335.8M | $90.0M |
| Short-term investments | $566.5M | $506.8M | $491.3M | $392.7M | $329.6M | $373.2M |
| Total debt | $2.4M | $2.9M | $3.3M | $3.7M | $4.1M | $3.5M |
| Total assets | $1.65B | $1.67B | $1.74B | $1.10B | $1.13B | $918.3M |
| Total liabilities | $136.2M | $129.4M | $163.1M | $155.8M | $159.6M | $132.1M |
| Shareholders' equity | $1.51B | $1.54B | $1.58B | $946.3M | $971.5M | $786.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology